Table 2 Association between demographic-clinical, and laboratory characteristics and death within 30 days post-systemic oncological therapy (bivariate analysis)
Characteristic | Overall, N = 891 | Survival of at least 30 days after therapy, N = 371 | Death within 30 days after therapy, N = 521 | p-value2 |
|---|---|---|---|---|
Age (years) | 59.28 (12.23) | 58.44 (11.55) | 59.89 (12.76) | 0.578 |
Male | 41 / 89 (46%) | 14 / 37 (38%) | 27 / 52 (52%) | 0.189 |
Race | 0.481 | |||
White | 50 / 89 (56%) | 18 / 37 (49%) | 32 / 52 (62%) | |
Black | 6 / 89 (7%) | 3 / 37 (8%) | 3 / 52 (6%) | |
Brown | 32 / 89 (36%) | 16 / 37 (43%) | 16 / 52 (31%) | |
Asian | 1 / 89 (1%) | 0 / 37 (0%) | 1 / 52 (2%) | |
Schooling | 0.541 | |||
Complete high school | 19 / 53 (36%) | 7 / 23 (30%) | 12 / 30 (40%) | |
Incomplete high school | 2 / 53 (4%) | 0 / 23 (0%) | 2 / 30 (7%) | |
Elementary school I | 12 / 53 (23%) | 6 / 23 (26%) | 6 / 30 (20%) | |
Elementary school II | 12 / 53 (23%) | 7 / 23 (30%) | 5 / 30 (17%) | |
Graduation | 2 / 53 (4%) | 1 / 23 (4%) | 1 / 30 (3%) | |
Incomplete higher | 1 / 53 (2%) | 1 / 23 (4%) | 0 / 30 (0%) | |
Illiterate | 5 / 53 (9%) | 1 / 23 (4%) | 4 / 30 (13%) | |
(Missing data) | 36 | 14 | 22 | |
Comorbidity | 73 / 89 (82%) | 30 / 37 (81%) | 43 / 52 (83%) | 0.845 |
Heart | 4 / 89 (4%) | 2 / 37 (5%) | 2 / 52 (4%) | > 0.999 |
Pulmonary | 9 / 89 (10%) | 5 / 37 (14%) | 4 / 52 (8%) | 0.481 |
Renal | 8 / 89 (9%) | 3 / 37 (8%) | 5 / 52 (10%) | > 0.999 |
Liver | 3 / 89 (3%) | 0 / 37 (0%) | 3 / 52 (6%) | 0.263 |
Autoimmune | 10 / 89 (11%) | 5 / 37 (14%) | 5 / 52 (10%) | 0.736 |
Degenerative orthopedic | 4 / 89 (4%) | 0 / 37 (0%) | 4 / 52 (8%) | 0.138 |
Vascular | > 0.999 | |||
Deep vein thrombosis | 3 / 7 (43%) | 2 / 5 (40%) | 1 / 2 (50%) | |
Aortic aneurysm | 2 / 7 (29%) | 1 / 5 (20%) | 1 / 2 (50%) | |
Stroke | 2 / 7 (29%) | 2 / 5 (40%) | 0 / 2 (0%) | |
(Missing data) | 82 | 32 | 50 | |
ECOG | < 0.001 | |||
2 | 44 / 89 (49%) | 27 / 37 (73%) | 17 / 52 (33%) | |
3 | 42 / 89 (47%) | 10 / 37 (27%) | 32 / 52 (62%) | |
4 | 3 / 89 (3%) | 0 / 37 (0%) | 3 / 52 (6%) | |
BMI (kg/m2) | 22.68 (18.61, 26.19) | 24.44 (19.65, 28.91) | 20.96 (18.33, 25.21) | 0.056 |
Smoking | 45 / 89 (51%) | 19 / 37 (51%) | 26 / 52 (50%) | 0.900 |
Alcoholism | 19 / 89 (21%) | 9 / 37 (24%) | 10 / 52 (19%) | 0.563 |
Diabetes mellitus | 22 / 89 (25%) | 8 / 37 (22%) | 14 / 52 (27%) | 0.568 |
Hypertension | 42 / 89 (47%) | 17 / 37 (46%) | 25 / 52 (48%) | 0.843 |
Number of metastasis sites | 2.00 (1.00, 3.00) | 2.00 (1.00, 2.00) | 2.00 (1.00, 3.00) | 0.326 |
Site | 0.865 | |||
Breast | 15 / 89 (17%) | 8 / 37 (22%) | 7 / 52 (13%) | |
Colon | 9 / 89 (10%) | 4 / 37 (11%) | 5 / 52 (10%) | |
Lung | 23 / 89 (26%) | 10 / 37 (27%) | 13 / 52 (25%) | |
Others | 29 / 89 (33%) | 11 / 37 (30%) | 18 / 52 (35%) | |
Ovary | 8 / 89 (9%) | 2 / 37 (5%) | 6 / 52 (12%) | |
Stomach | 5 / 89 (6%) | 2 / 37 (5%) | 3 / 52 (6%) | |
Hormone therapy | 6 (7%) | 5 / 37 (14%) | 1 / 52 (2%) | 0.078 |
Dose reduction of CTx | 18 (20%) | 0 (0%) | 18 (35%) | < 0.001 |
Admission to ICU | 18 (20%) | 7 (19%) | 11 (21%) | 0.796 |
Orotracheal intubation or mechanical ventilation | 16 (18%) | 7 (19%) | 9 (17%) | 0.845 |
Central venous catheter | 29 (33%) | 12 (32%) | 17 (33%) | 0.979 |
Blood transfusion | 13 (15%) | 4 (11%) | 9 (17%) | 0.392 |
Cardiopulmonary resuscitation | 15 (17%) | 7 (19%) | 8 (15%) | 0.661 |
Previous lines of chemotherapy | 19 (21%) | 7 (19%) | 12 (23%) | 0.637 |
Hemoglobin | 9.99 (1.96) | 10.53 (2.00) | 9.61 (1.86) | 0.031 |
Hematocrit | 30.00 (5.75) | 31.43 (6.06) | 28.98 (5.35) | 0.052 |
Leukocytes | 12,200.00 (9,400.00, 15,100.00) | 9,800.00 (7,700.00, 14,000.00) | 13,550.00 (10,350.00, 17,125.00) | 0.002 |
Neutrophils | 8,820.00 (6,870.00, 13,000.00) | 7,420.00 (6,200.00, 10,800.00) | 10,285.00 (8,100.00, 14,060.00) | 0.012 |
Platelets | 296,000.00 (210,000.00, 407,000.00) | 282,000.00 (203,000.00, 377,000.00) | 318,500.00 (224,250.00, 456,750.00) | 0.125 |
Aspartate aminotransferase | 28.00 (19.00, 73.00) | 24.50 (19.00, 40.75) | 31.00 (19.00, 103.10) | 0.198 |
(Missing data) | 26 | 9 | 17 | |
Alanine aminotransferase | 28.00 (13.00, 58.45) | 24.00 (13.50, 35.50) | 31.00 (12.50, 69.00) | 0.387 |
(Missing data) | 26 | 9 | 17 | |
Total bilirubin | 0.40 (0.30, 1.25) | 0.35 (0.20, 0.62) | 0.60 (0.30, 1.55) | 0.074 |
(Missing data) | 26 | 9 | 17 | |
Direct bilirubin | 0.20 (0.20, 1.10) | 0.20 (0.18, 0.32) | 0.40 (0.20, 1.45) | 0.046 |
(Missing data) | 26 | 9 | 17 | |
Ionized calcium | 5.30 (5.00, 5.57) | 5.30 (5.10, 5.60) | 5.20 (5.00, 5.50) | 0.054 |
(Missing data) | 3 | 0 | 3 | |
Creatinine | 0.70 (0.50, 0.90) | 0.60 (0.40, 0.90) | 0.70 (0.50, 1.02) | 0.173 |
Urea | 40.00 (25.00, 63.00) | 31.00 (22.00, 50.00) | 43.00 (31.00, 76.75) | 0.003 |
Creatinine clearance | 92.08 (63.95, 133.88) | 120.68 (78.62, 157.36) | 78.19 (57.02, 118.87) | 0.011 |
Uric acid | 3.90 (2.40, 4.55) | 4.00 (2.05, 4.40) | 3.75 (2.93, 4.78) | 0.738 |
(Missing data) | 66 | 30 | 36 | |
Albumin | 2.90 (2.30, 3.40) | 3.40 (2.98, 3.50) | 2.40 (2.20, 3.00) | 0.001 |
(Missing data) | 52 | 21 | 31 | |
Lactate dehydrogenase | 378.50 (218.75, 550.75) | 374.00 (213.00, 464.50) | 391.00 (259.00, 694.00) | 0.261 |
(Missing data) | 69 | 26 | 43 | |
C-reactive protein | 71.50 (39.75, 156.25) | 54.00 (27.00, 126.00) | 96.00 (50.75, 172.50) | 0.010 |
(Missing data) | 1 | 0 | 1 |